Compare AARD & YCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AARD | YCY |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 150.0M |
| IPO Year | 2025 | 2025 |
| Metric | AARD | YCY |
|---|---|---|
| Price | $7.21 | $10.22 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $15.29 | N/A |
| AVG Volume (30 Days) | ★ 137.9K | 3.1K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $9.90 |
| 52 Week High | $17.94 | $10.24 |
| Indicator | AARD | YCY |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 63.73 |
| Support Level | $4.99 | $9.95 |
| Resistance Level | $7.92 | $10.24 |
| Average True Range (ATR) | 0.71 | 0.00 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 60.28 | 77.78 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
AA Mission Acquisition Corp II is a blank check company formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities.